CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 11 new non-executive employees as part of its 2025 Inducement Plan. The awards, approved on August 15, 2025, were authorized by the company’s independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
In total, the employees received 6,940 time-based restricted stock units, which will vest in four equal installments on the first through fourth anniversaries of the grant date. Vesting remains contingent upon each employee’s continued employment with the company.
Madrigal Pharmaceuticals specializes in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and continues to expand its workforce to support ongoing research and growth initiatives.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.